Benzinga | Feb 12, 2021 06:43AM EST

Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $180

Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $160 to $180.